{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -1.97, "epsForward": -2.15, "epsCurrentYear": -1.6, "priceEpsCurrentYear": -23.499998, "sharesOutstanding": 63121800, "bookValue": 11.528, "fiftyDayAverage": 34.188, "fiftyDayAverageChange": 3.4119987, "fiftyDayAverageChangePercent": 0.09980106, "twoHundredDayAverage": 35.48, "twoHundredDayAverageChange": 2.119999, "twoHundredDayAverageChangePercent": 0.059751943, "marketCap": 2373379584, "forwardPE": -17.48837, "priceToBook": 3.2616239, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.3 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 37.6, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 5, "fiftyTwoWeekLowChange": 12.999998, "fiftyTwoWeekLowChangePercent": 0.5284552, "fiftyTwoWeekRange": "24.6 - 39.8", "fiftyTwoWeekHighChange": -2.2000008, "fiftyTwoWeekHighChangePercent": -0.0552764, "fiftyTwoWeekLow": 24.6, "fiftyTwoWeekHigh": 39.8, "earningsTimestamp": 1683664200, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1417676400000, "priceHint": 2, "marketState": "REGULAR", "regularMarketChange": 0.19999695, "regularMarketTime": 1683871252, "regularMarketDayHigh": 37.6, "regularMarketDayRange": "37.6 - 37.6", "regularMarketDayLow": 37.6, "regularMarketVolume": 50, "regularMarketPreviousClose": 37.4, "bid": 37.4, "ask": 37.8, "bidSize": 1000, "askSize": 1000, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": 0.5347512, "regularMarketPrice": 37.6, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "XENON PHARMACEUTICALS", "longName": "Xenon Pharmaceuticals Inc.", "messageBoardId": "finmb_565718", "market": "dr_market", "symbol": "XP0.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3650 Gilmore Way", "address2": "Suite 200", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 203, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA", "age": 46, "title": "Pres, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 973760, "fmt": "973.76k", "longFmt": "973,760"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 21407696, "fmt": "21.41M", "longFmt": "21,407,696"}}, {"maxAge": 1, "name": "Ms. Sherry  Aulin", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": {"raw": 3034240, "fmt": "3.03M", "longFmt": "3,034,240"}, "exercisedValue": {"raw": 607697, "fmt": "607.7k", "longFmt": "607,697"}, "unexercisedValue": {"raw": 1773229, "fmt": "1.77M", "longFmt": "1,773,229"}}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 54, "title": "Chief Legal Officer & Corp. Sec.", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 200510, "fmt": "200.51k", "longFmt": "200,510"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.", "age": 43, "title": "Chief Commercial Officer", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 618068, "fmt": "618.07k", "longFmt": "618,068"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2267715, "fmt": "2.27M", "longFmt": "2,267,715"}}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 684218, "fmt": "684.22k", "longFmt": "684,218"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1210719, "fmt": "1.21M", "longFmt": "1,210,719"}}, {"maxAge": 1, "name": "Ms. Shelley  McCloskey B.A.", "age": 62, "title": "Exec. VP of HR", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 61, "title": "Exec. VP of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 61, "title": "Exec. VP of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sheila M. Grant M.B.A., M.Sc., MBA", "title": "Exec. VP of R&D Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}